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ABSTRACT
Introduction Crohn’s perianal fistulas are challenging 
for patients and clinicians. Many do not respond to 
available treatments and despite recommendations by a 
global consensus, there are currently no specific patient- 
derived quality of life tools to measure response to 
treatment. We present a new validated patient- reported 
outcome measure (PROM) for this complicated disease 
phenotype.
Methods A draft questionnaire was generated 
using unstructured qualitative patient interviews on 
the experience of living with Crohn’s perianal fistula, 
a nationwide multidisciplinary consensus exercise, 
a systematic review of outcomes assessing medical/
surgical/combined treatment and a patient and public 
involvement day. Psychometric properties were assessed 
including construct validity (by comparison with the 
Hospital Anxiety and Depression Scale (HADS) and the 
UK Inflammatory Bowel Disease Questionnaire (UK- 
IBDQ)), and reliability and responsiveness was assessed 
by test–retest analysis.
Results Data from 211 patients contributed to 
development of a final 28- item questionnaire. 
The Crohn’s Anal Fistula Quality of Life (CAF- QoL) 
demonstrated good internal consistency (Cronbach’s 
alpha 0.88), excellent stability (intraclass correlation 
0.98) and good responsiveness and construct validity, 
with positive correlation with the UK- IBDQ and HADS.
Conclusion The CAF- QoL scale is ready for use as a 
PROM in research and clinical practice. It complements 
objective clinical evaluation of fistula by capturing impact 
on the patient.
INTRODUCTION
Perianal fistulas occur in a third of all patients with 
Crohn’s disease (CD).1 They represent a distinct 
and aggressive phenotype of CD1 2 and often 
follow a chronic course with symptoms including 
anal pain and purulent discharge, commonly 
leading to a severely impaired quality of life (QoL). 
Crohn’s perianal fistulas are challenging to treat; 
often complex in nature, they can be refractory 
to conventional medical treatment strategies such 
as antibiotics, immunomodulators3 4 and biologic 
drugs, such as anti- tumour necrosis factor agents.5–9 
Surgical treatments fare little better and despite 
a multidisciplinary approach (ie, concomitant 
surgical and medical therapies), most patients expe-
rience recurrence or persistence. The associated 
morbidity of the disease and its treatment can have 
profound effects on patients’ physical and psycho-
social well- being.
In clinical trials, success is usually measured by 
clinical assessment of closure of fistula tracks, some-
times accompanied by radiological assessment of 
‘healing’. This is appropriate in trials of treatment 
with ‘curative intent’, but as most patients do not 
Significance of this study
What is already known on this subject?
 ► There is heterogeneity in outcome 
measurement in Crohn’s perianal fistula, 
limiting comparison of treatment options, 
with no widely accepted gold standard. There 
is currently no patient- reported outcome 
measure (PROM) for Crohn’s perianal fistula, 
representing an unmet need, which was 
highlighted in a published core outcome set for 
perianal Crohn’s disease.
What are the new findings?
 ► The development and initial validation of a new 
PROM for Crohn’s perianal fistula, the Crohn’s 
Anal Fistula Quality of Life scale.
How might it impact on clinical practice in the 
foreseeable future?
 ► This new PROM lends itself to utility in clinical 
trial design for Crohn’s perianal fistulas, 
enabling consistency in data sets collected in 
this condition. It also has the potential utility of 
assessment of disease impact in a clinic setting, 
to guide stratification of patients according 
to severity of disease impact and tailor 
appropriate management.
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achieve sustained fistula closure, there is a need to measure any 
benefit produced by treatments in situations where fistulas do 
not ‘heal’. Further, it is important to assess additional impacts of 
any intervention on QoL even if successful ‘healing’ occurs. For 
example, continence impairment might occur after a ‘curative’ 
fistulotomy or advancement flap repair. There are also interven-
tions, such as setons, which are not designed to heal fistulas and 
are performed with intent to ameliorate symptoms rather than 
cure. QoL assessment may represent the primary outcome in 
such situations.
The only current measure designed to assess Crohn’s perianal 
fistula activity and its impact on QoL is the Perianal Disease 
Activity Index (PDAI).10 This clinical assessment tool aims to 
measure disease activity in patients with Crohn’s perianal fistulas. 
It assesses pain, restriction of physical and sexual activities, and 
perianal disease severity (discharge, disease type and induration). 
Items are scored from 0 (no problem) to 4 (severe problem) on 
a Likert scale.10–12 Although the PDAI was developed to measure 
clinical disease activity in patients with ‘perianal disease’, it is 
not specific to perianal fistula and was not developed using 
methodology that conformed to accepted principles of evalua-
tive index development.13 A significant limitation to its use as a 
patient- reported outcome measure (PROM) is the lack of patient 
involvement in its development, relying instead on QoL issues 
which physicians believed to be important to patients. Thus, it 
does not assess the global QoL impact of fistulas on patients, and 
its relevance to what patients themselves consider as important is 
unknown. Recent guidelines recommend that improved instru-
ments are needed to score perianal CD fistula activity and impact 
on QoL.8 In particular, a tool which assesses the impact of fistu-
la(s) on a patient’s QoL and which detects a meaningful change 
in their QoL after treatment is required. Early exploratory quali-
tative work demonstrates that the impact of CD perianal fistulas 
extends far beyond restricting daily and sexual activities14 15 and 
a patient- centred, patient- derived tool is needed. We aimed to 
develop and undertake initial psychometric validation of a new 
QoL scale for patients with CD with perianal fistulas ensuring 
patients were involved in all phases of development.
METHODS
Overview
The study used a three- phase mixed methods design using an 
exploratory instrument development model16 17 to support a 
QoL PROM development process.18 Phase 1 used an explor-
atory qualitative approach19 to create a long list of items. Phase 
2 involved cognitive interviews to refine items. Phase 3 subjected 
the draft PROM to psychometric testing via completion by 
participants with Crohn’s perianal fistula and completed final 
item reduction.
Study steering group and patient and public involvement
Members of the study steering group included all relevant 
stakeholders: a colorectal surgeon with expertise in fistulas, a 
gastroenterologist with expertise in IBD, IBD specialist nurses 
(2), researchers with experience in PROM design (3)20 and 
patient representatives (4). The latter constituted our patient and 
public involvement (PPI) team and consisted of four members 
of Crohn’s and Colitis UK (CCUK) charity. All had CD and 
previous or current experience of living with a perianal fistula. 
The PPI team helped with analysis and contributed to discussion 
and development of the preliminary items for the draft ques-
tionnaire and final item reduction. The study design was also 
presented at a dedicated PPI day for critical feedback and to 
gather suggestions to optimise recruitment and response rates.
Recruitment and sampling
Participants were recruited using purposive sampling from the 
membership (via advertisement) of collaborating registered 
patient charities including those specific to IBD/bowel diseases 
(ForCrohn’s, CCUK, Bowel Disease Research Foundation) and 
UK- wide patient repositories (UK IBD BioResource). Recruit-
ment also occurred via IBD outpatient clinics, aiming to recruit 
equal numbers of men and women, with a broad age range.
Selection of participants
Inclusion criteria: Over 16 years; living in the UK; diagnosis of 
CD with perianal fistula; ability to read, speak and understand 
English; ability to give informed consent.
Exclusion criteria: Patients with resolved fistulas were excluded 
from phase 3 and participants contributing to any phase of the 
study were excluded from contribution to another.
Data collection/generation of a draft PROM
Phase 1: experience interviews/data from outcomes review and 
consensus exercise
(A) Individual unstructured interviews were conducted face to 
face or by telephone/video call according to participant prefer-
ence, to explore the experience of living with CD- related peri-
anal fistula(s) and the impact of the disease and surgical and/
or medical treatments on the individual. This facilitated an 
in- depth understanding of the complex experience of living with 
Crohn’s perianal fistulas. Interviews were digitally recorded and 
transcribed verbatim by a professional transcriber. A thematic 
analysis15 21 22 was undertaken to generate a long list of items for 
inclusion in the draft PROM. Individual followed by steering 
group analysis and agreement ensured that findings represented 
a consensus of the steering group.15 22
(B) To enhance the face and content validity of the ques-
tionnaire, we included data from a systematic review of fistula 
outcome measures and a consensus exercise undertaken to 
develop a core outcome set (COS) for Crohn’s perianal fistulas.23 
The systematic review followed the Preferred Reporting Items for 
Systematic Reviews and Meta- Analyses guidelines and involved 
a search limited to studies conducted in adults aged ≥18 years 
and papers published between 1 January 2010 and 12 July 2016. 
Reference lists were searched to ensure complete capture. We 
assessed the results to identify patient- reported outcomes and 
included these in the long list of items for the draft PROM. The 
COS involved stakeholder recruitment from across the UK,23 
including clinicians (colorectal surgeons, gastroenterologists, 
radiologists and IBD nurses) and patients, the latter being the 
primary stakeholders. Qualitative data from patient focus groups 
(discussing QoL and outcome measurements) in the COS exer-
cise were discussed by the consensus steering group and included 
in the long list of items for the draft PROM.
At the end of phase 1, items for inclusion in the PROM (the 
Crohn’s Anal Fistula Quality of Life (CAF- QoL) scale) were 
collated using a mixture of questions and statements. Scoring 
systems (mixture Likert scale/closed- ended ordinal answers) 
were added following steering group consensus. A background 
section (16 questions) collected demographic data and disease 
details (including duration, number of fistulas, medication and 
surgical history). This section also had an anchor question 
using a 10- point Likert scale to measure self- reported global 
 on M












3Adegbola SO, et al. Gut 2020;0:1–8. doi:10.1136/gutjnl-2019-320553
Inflammatory bowel disease
rating of fistula status. This enabled transitional analysis on 
the basis of the participants’ subjective perceptions of their 
fistula.
Phase 2: cognitive interviews/pretesting of draft PROM
Participants in this phase provided further content validation via 
four cognitive interview rounds (involving three to four indi-
vidual interviews per round), to enable participants to refine 
the questions using think- aloud techniques and verbal probing 
as they completed the draft PROM. Interviews were digitally 
recorded and transcribed by a professional transcriber. Following 
each round of cognitive interviews, items were reviewed by the 
steering group to ensure any suggested changes were agreed 
by consensus. Subsequent rounds of interviews were used to 
confirm acceptability until data saturation was achieved and no 
new suggestions were received.
Phase 3: testing of the new CAF-QoL PROM
Participants with CD and active (ie, presence of symptoms 
related to) perianal fistulas were sent the draft CAF- QoL 
PROM by post or online and asked to complete it again 2 weeks 
later for test–retest reliability. At the initial administration of 
the CAF- QoL PROM, participants were also asked to complete 
a demographic details form, the validated UK- IBDQ24 and 
the Hospital Anxiety and Depression Scale (HADS).25 Overall 
and perianal fistula disease activity information was collected 
on both occasions using a modified version of the Harvey- 
Bradshaw Index (HBI)26 27 and self- reported global rating of 
fistula status. This allowed stratification according to change in 
overall disease activity level between the test and retest analysis 
and allowed a subanalysis for sensitivity to change in fistula 
status.
Testing of psychometric properties
Validity
Content validity assessed the applicability, relevance and clarity 
of question items in order to maximise the accurate completion 
of the questionnaire. Further to verification of content validity 
in phases 1 and 2, it was explored by evaluating the levels of 
missing data per item in phase 3. The overall response rate 
was analysed to indicate the feasibility of the questionnaire for 
self- completion.
Construct validity assessed the consistency of the scale with 
other instruments known to assess similar attributes with good 
validity and reliability. Two validated outcome measures (UK- 
IBDQ24 and HADS25) were used as comparators to evaluate the 
relationships between patients’ reports as these measures cover 
some similar concepts. Correlation was assessed using Pearson’s 
correlation coefficient (r).
Reliability
Test–retest reliability (reproducibility or stability) assessed 
consistency between the two completions of the draft CAF- 
QoL.28 29 Respondents completing the phase 3 test–retest in 
whom the IBDQ, HADS and anchor questions indicated stable 
disease were used to assess reliability.24 30 31 Relevant anchor 
questions were a general rating of fistula status (on a Likert scale 
of 0–10) and a question ascertaining whether there had been 
any flare- up of their fistula (requiring medication, operation or 
seton) since the previous questionnaire completion. Those who 
reported no changes (absence of flare- up, <1 point difference on 
Likert scale and stable overall IBD disease activity as defined by 
stable HBI scores) were included in the reproducibility analysis. 
The difference between test and retest responses was appraised 
using weighted statistics (the weighted kappa method32 33) due 
to the categorical nature of response options. Kappa is measured 
on a scale ranging up to a maximum agreement of 1, with values 
signifying a good (>0.6) and very good (>0.8) strength of agree-
ment.34 Reproducibility of the total CAF- QoL scores for stable 
patients was also assessed using the intraclass correlation (ICC) 
coefficient. The ICC is the proportion of total variation in CAF- 
QoL scores between test and retest completions that is due to 
variation between respondents (inter- respondent variation), as 
opposed to variation within respondents (intrarespondent vari-
ation). A high agreement between test and retest scores implies 
little intraparticipant variation and thus an ICC value close to 
1 with values exceeding 0.75 generally accepted as a marker of 
good reproducibility.28





  Female 122 57.8
  Male 88 41.7
  Transgender 1 0.5
  Age* 42.9±12.7*
  Duration of Crohn’s disease (years)
  <1 7 3.3
  1–4 31 14.7
  5–9 47 22.2
  10–14 34 16.1
  15+ 92 43.6
  Duration of perianal fistula (years)
  <1 18 8.5
  1–4 67 31.8
  5–9 61 28.9
  10–14 25 11.8
  15+ 40 18.9
  Current/previous medication for perianal 
fistula
  No 182 86.3
  Yes 29 13.7
Previous surgery for perianal fistula
  No 61 28.9
  Yes 150 71.1
  Previous seton
  Yes 131 62.1
  No 59 27.9
  Unsure 21 10.0
Stoma due to perianal fistula
  Yes 31 14.7
  No 180 85.3
Self- reported global fistula rating†
Remission (0) 21/184‡ 11.4
Mild (1–3) 42/184 22.8
Moderate (4–6) 43/184 23.3
  Severe (≥7) 78/184 42.4
*Mean±SD reported.
†Rating on 10- point Likert scale.
‡Denominator is 184, that is, number of phase 3 respondents.
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Sensitivity to change
Sensitivity to change (or responsiveness) was assessed in retested 
patients who reported significant change (ie, three or more 
points on the Likert scale) in their general rating of fistula 
status. Comparisons between baseline and retest overall CAF- 
QoL scores were assessed using mean change between successive 
completion scores, with a corresponding CI. Changes with p 
values <0.05 were deemed significant.
Item reduction: questionnaire refinement
Factor analysis (FA) with principal axis factoring extraction and 
varimax rotation were used to determine individual dimensions 
or subscales of the CAF- QoL and to refine the number of items.35 
The internal reliability (ie, correlation between different items) 
was determined using Cronbach’s alpha (values exceeding 0.7 
indicate good consistency).28 The strength of association between 
individual questions was assessed using Pearson’s correlation 
coefficient. Those with strong associations (correlation coeffi-
cient >0.75) were reviewed by the steering group to achieve 
consensus on excluding questions deemed to duplicate informa-
tion and those unlikely to change with intervention. Conten-
tious items were discussed, and consensus agreed on exclusion 
of questions following review of those with missing data from 
a majority of participants (regardless of fistula status), questions 
with poor test–retest agreement (suggesting unreliability), ques-
tions with strong associations with others (ie, suggesting dupli-
cated themes) and questions with poor spread of response.
RESULTS
A total of 211 participants with Crohn’s perianal fistula were 
involved in the three study phases (table 1). Most participants 
(~60%) reported having IBD for longer than 10 years and over 
80% had experienced Crohn’s perianal fistulas for at least 1 year. 
Fewer than 15% had a stoma (temporary or permanent).
Devising and pretesting the draft CAF-QoL scale: phases 1 
and 2
Twelve interviews were conducted (median of 43 min, range 
18–145 min) achieving apparent data saturation. Three broad 
themes emerged: burden of symptoms, burden of treatment and 
impact on emotional, physical and social well- being (figure 1). 
Each included several subthemes, with considerable interplay 
between these.15 The impact of perianal fistula(s) on patients 
with CD was intense and wide reaching, negatively affecting 
intimate, close and social relationships and causing losses in 
life and work- related opportunities.36 Data from the quali-
tative interviews were combined with those from the COS 
exercise which involved more than 230 stakeholders from 
across the UK,23 including 80 patients with Crohn’s perianal 
fistula. Data from the COS included the systematic review of 
patient- reported outcomes, qualitative data from patient focus 
groups and the final list of core outcomes. An original long 
list of 45 items was collated for the draft PROM and these 
were reviewed by the steering group, reducing these to 35 
items following elimination of repetition and overlap. Those 
retained were grouped under three domains (A–C) mirroring 
the broad themes described above and converted into questions 
(Domain A—symptoms) and statements (Domain B—treat-
ment and Domain C—QoL impact). Likert scales were adopted 
measuring frequency (0–4) in domain A, and degree of agree-
ment (Likert scales 0–4) in domains B and C. The questions 
and statements were phrased to ensure that positive answers 
(indicating good QoL) were always at the lower end of the 
Likert scale, and higher scores indicated worse QoL. Pretesting 
occurred during cognitive interviews (n=15; average question-
naire completion time was 9 min) and no additional items were 
suggested for inclusion.
Figure 1 Thematic depiction of the experiences of living with Crohn’s anal fistula Themes are located in the central circles with the subthemes in 
the peripheries
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Testing the CAF-QoL: phase 3
Patient sample
The test data consisted of responses from 184 patients. Three 
(1.6%) were excluded due to excessive missing data leaving 
181 CAF- QoL questionnaires for analysis. The retest data had 
a response rate of 79% (143/181) completing the questionnaire.
Data spread and completeness
Results of the test data indicated that the majority of responses 
were spread across the available categories, demonstrating that 
the questionnaire can discriminate between patients with a 
range of symptoms and concerns. There were little missing data 
with fewer than 1% of respondents missing sporadic responses. 
Most questions were applicable to the majority of respondents. 
Some questions had ‘not applicable’ responses. These were the 
questions relating to presence of seton or side effects of medi-
cation and was highest for the question relating to presence of 
a stoma (not applicable to 83% of respondents). Analysis of the 
association between questions demonstrated that there were no 
‘perfect’ correlations, with no correlation coefficient over 0.9. 
Therefore, no questions were perfectly duplicating information. 
However, there were some strong associations between ques-
tions (correlation coefficient >0.8), and these were considered 
for item reduction.
Item reduction
Nine questions were removed from the final CAF- QoL (see online 
supplemental appendix 1 for item reduction overview). Three 
questions pertaining to symptoms (domain A) were removed. 
Two of these had very little spread in response categories, with 
low SD, and responses were grouped towards the lower end of 
the Likert scale (indicating minimal relevance to most respon-
dents). These questions related to the use of painkillers and the 
association of urinary tract infections to the fistula. One question 
relating to the use of pads or gauze for the discharge from the 
fistula was removed due to strong association with the preceding 
question on fistula discharge, with consensus decision that there 
was probable overlap in the item being assessed. Four questions 
relating to fistula treatment (domain B) were removed due to 
poor spread and poor test/retest agreement (in those reporting 
no change in global fistula status). Two questions relating to QoL 
impact (domain C) were removed. These questions involving 
fistula effect on intimacy and career progression were found to 
be strongly associated with other questions (correlation coeffi-
cient >0.83), replicating themes.
The final version of the questionnaire included 28 items, 27 
of which were scored from 0 to 4, plus one free- text question 
(figure 2), giving a score range of 0–108. Data from 181 respon-
dents demonstrated scores of 0–95 (possible range 0–108), 
as depicted in figure 3. Scores were approximately normally 
distributed with a mean score of 42.0, and an SD of 26.0.
Internal consistency and FA
Cronbach’s alpha was 0.88, demonstrating a good degree of 
internal consistency among the individual items. An FA was 
performed to determine if the score naturally broke down into 
different subscales. Only one factor was found to be significant, 
encompassing the majority of questions, indicating no subscales.
Reliability (agreement between test and retest scores)
Sixty- nine patients of the 143 retest respondents (48%) met the 
criteria for disease stability (as defined by ≤1 point difference 
Figure 2 The Crohn's Anal Fistula Quality of Life (CAF- QoL) scale.
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between test/retest scores on global self- rating of fistula status, 
and stable disease on HBI and no fistula flare between test/retest 
completion). Weighted kappa was >0.7 for all items, demon-
strating very good agreement. The mean difference between the 
retest and test measurements (calculated as retest minus test) was 
−0.6 with an SD of 6.0. The agreement between test and retest 
scores was also examined using ICC method. This method gave 
an ICC value of 0.98 (95% CI 0.96 to 0.99). This high value 
demonstrated very good agreement between the test and retest 
scores.
Sensitivity to change
In order to examine the change in CAF- QoL total score between 
test and retest in specific groups of patients, three groups were 
examined relating to patients with ‘stable’, ‘improving’ and 
‘worsening’ global fistula rating (table 2). In patients with stable 
disease there was no significant change in CAF- QoL scores 
between the two time points. CAF- QoL scores decreased signifi-
cantly at the retest time point in those with improved disease, by 
an average of 4 units. Conversely in those with worsening global 
fistula rating scores increased significantly between time points, 
by a mean of 7 units.
Association with other health-related measures
Assessment of the agreement between the total CAF- QoL scores 
and other health- related measures (UK- IBDQ/HADS) used 
Pearson’s correlation (table 3). The results demonstrated signifi-
cant positive correlations between the total CAF- QoL score and 
each of the other measures. Higher CAF- QoL scores were associ-
ated with higher levels of anxiety and depression, and also worse 
IBDQ scores.
DISCUSSION
The CAF- QoL questionnaire scale has demonstrated good reli-
ability, internal consistency and face/content validity. The robust-
ness of the questionnaire is confirmed through the rigorous 
developmental process, with participants with Crohn’s peri-
anal fistula contributing throughout, as participants and on the 
steering group. This has ensured that the language is straightfor-
ward, using lay terms that increase readability and enable accu-
rate interpretation, and that the content is relevant to patients.
There is limited evidence in the literature on QoL in patients 
with anal fistula. Reported patient assessment of interventions 
highlights that patients have concerns with regard to anal fistulas 
and the treatment options; however, data collection is often 
rudimentary, involving patient satisfaction or incontinence.37 38 
The absence of a validated PROM means patients’ concerns are 
often expressed based on clinicians’ perspectives and this was 
highlighted in an Australian study by Wong et al39 comparing 
surgeon and patient preferences for surgical operations for idio-
pathic anal fistulas. The different cure and incontinence rates 
for each procedure were quoted for the patients to consider 
and their preferences explored. A clear mismatch was reported 
between what the surgeons and patients felt were important 
QoL issues. For example, 91% of surgeons versus 25% of 
patients nominated continence as an important QoL issue.39 The 
study demonstrated the potential assumptions made by clinicians 
with regard to the impact of fistula surgery on patients’ QoL. 
More recently, Ferrer- Marquez et al40 developed a QoL ques-
tionnaire in patients with (non- Crohn’s) anal fistula; however, 
major limitations of this study were the testing on a small sample 
(n=54) of Spanish- speaking patients, and crucially patients were 
not included in the initial development of the questionnaire. 
There is no objective patient- centred disease scoring tool for 
Crohn’s perianal fistula and this results in an inability to quan-
tify adequately the effect of Crohn’s fistulas on psychosocial 
well- being and has led to calls to address the unmet need for a 
disease- specific PROM.41
Study strengths and limitations
The strength of the study lies in its design, incorporating a 
literature review, consensus exercise, patient focus groups and 
individual patient interviews19 (unstructured and cognitive) 
to inform the item generation. Recruitment of participants 
occurred via nationwide charities, hospitals and social media, 
ensuring a broad sample of those with experience of Crohn’s 
perianal fistulas. The involvement of patients both as partici-
pants and in the steering group ensured their voice was central to 
Figure 3 Histogram of total CAFQOL scores. CAF- QoL, Crohn’s Anal 
Fistula Quality of Life.







Mean (95% CI) P value
Stable* 69 41.5±28.4 40.9±27.8 −0.6 (−2.0 to 0.9) 0.46
Improved† 12 52.2±20.7 48.2±22.3 −4.0 (−7.0 to −1.0) 0.01
Worsening‡ 9 30.1±17.3 37.7±21.5 7.6 (1.6 to 13.5) 0.02
n denotes number of patients fulfilling criteria for analysis.
Values in bold demonstrate statistical significance with p value <0.05.
*Defined as self- reported global fistula rating test/retest scores differing by no more 
than 1 point, no fistula flare- up and same test/retest Harvey- Bradshaw criteria.
†Defined as self- reported global fistula rating retest score ≥3 units lower than the 
test score.
‡Defined as self- reported global fistula rating retest score ≥3 units higher than the 
test score.
CAF- QoL, Crohn’s Anal Fistula Quality of Life.
Table 3 Association between CAF- QoL scores and other health 
scores
Variable n Correlation coefficient P value
HADS anxiety 174 0.52 <0.001
HADS depression 174 0.53 <0.001
UK- IBDQ 176 0.58 <0.001
n denotes number of respondents with completed questionnaires.
CAF- QoL, Crohn’s Anal Fistula Quality of Life; HADS, Hospital Anxiety and 
Depression Scale; UK- IBDQ, UK Inflammatory Bowel Disease Questionnaire.
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every stage of the process, facilitating creation of a true PROM. 
This is often lacking in PROM development.42 Another strength 
was the diversity of stakeholders in the steering group (patient 
representatives, gastroenterologist, colorectal surgeon, specialist 
nurses, qualitative researchers) while ensuring that patient input 
was always prioritised.
Limitations include the absence of data collected on other 
manifestations of perianal CD which often coexist with fistulas. 
This was a deliberate decision based on a consensus view to 
create a fistula- specific PROM. Another potential limitation 
was the lack of access to exact data, for example, MRI and 
other anatomic fistula data for participants recruited via char-
ities. However, the large number of patients contributing to 
the CAF- QoL as well as the recruitment strategy (ie, recruited 
from various locations and not just tertiary centres) means that a 
spread of fistula/inflammatory characteristics is to be expected. 
Furthermore, patients reported different levels of symptoms 
at different points in the process (the basis of the test–retest 
phase) and were asked to describe the longitudinal history of 
their fistula during the interview stage so we would expect varia-
tion in fistula ‘phenotype’. Regarding analysis, respondents with 
temporary defunctioning stomas as opposed to following proc-
tectomy did not have separate analyses assessing the influence of 
either intervention on QoL. The group consensus was that such 
patients might well have different priorities, goals and symp-
toms, and separate analysis might have contributed to a score 
which was useful for neither group. During the data collection, 
those with stomas had no CD- specific marker of disease activity 
pertaining to looser stool, and the HBI question on diarrhoea 
may have been ambiguous for these patients. However, only 
14.6% (31/211) of the entire study cohort and 25/184 (13.6%) 
of the test–retest respondents had stomas and we made the 
assumption that disease activity might affect the fistula symp-
toms less in defunctioned patients, and thus not compromise the 
integrity of the score. In the analysis process, there were fewer 
numbers in the sensitivity to change/responsiveness analysis and 
a self- reported global fistula rating was used as a marker to assess 
transition in fistula status due to absence of a widely accepted/
reliable clinical measure. Indeed, responsiveness and stability 
calculations were limited by the fact that there is no true gold 
standard to define a change in disease state. However, use of 
subjective transition questions is an accepted technique used in 
several outcome measure studies and can be advantageous in 
assessment of QoL because it directly addresses patients’ percep-
tions of change over time and is short and simple.24 29–31
Clinical usefulness and future direction
Assessing QoL in patients with IBD is an important component of 
medical and surgical management and clinical decision- making, 
and the last decade has seen a rapid increase in the number of 
measures to assess the QoL in patients with IBD.43 There was 
previously no validated outcome measure that captured the 
patients’ evaluation of the effect of interventions for Crohn’s 
perianal fistulas on their well- being. This has importance in the 
face of elusive cure/non- sustained fistula closure, and is equally 
valuable as a secondary outcome measure for determining the 
impact of interventions in studies with curative intent, and as a 
primary outcome in studies of disease or symptom- ameliorating 
interventions.44 The CAF- QoL is the first disease- specific PROM 
in Crohn’s perianal fistula developed with a patient- centred 
methodology. Completion takes about 9 min on average and 
can be done with the clinician present or independently by the 
patient, with the goal of assessing the benefit of interventions 
in clinical trials, both medical and surgical, as well as defining 
disease impact and severity in the clinical setting to aid decision- 
making. It may also play a role in highlighting changing concerns 
and priorities that arise for patients between remission and 
relapse, which may guide individualised patient advice and 
support. Future research will include validation of its use in clin-
ical trials, measuring the CAF- QoL scale scores and determining 
if scores correlate with fistula activity levels and what constitutes 
a clinically significant response.
The currently available PDAI was developed to measure clin-
ical disease activity in patients with ‘perianal disease’ and despite 
its use in clinical trials,41 it is not specific to perianal fistula. It 
was strongly considered for adjunctive use in this study, but we 
elected to go with a pragmatic recruitment strategy that obviated 
the need for clinical assessment of all patients (including those 
recruited via charities for questionnaire testing), which would 
have otherwise been required to ensure robust completion of 
the PDAI.
Future studies will use PDAI in addition to CAF- QoL (we 
hope) to enable comparison. There is also ongoing work to 
aiming to improve the objective measures available for assessing 
perianal fistula disease activity (eg, using MRI13). In addition, 
a comprehensive classification for Crohn’s perianal fistulas, 
which integrates all elements that are important for medical 
and surgical management, is required and may need to incor-
porate a combination of diagnostics (endoscopy/MRI/endo-
anal ultrasound) and examination under anaesthesia to ensure 
robustness. Ongoing refinement and validation of CAF- QoL will 
ultimately aid the utility of this PROM alongside an objective 
clinical outcome measure, both of which are necessary tools in 
the evaluation of perianal fistula. The CAF- QoL scale will also 
need translation into different languages and cross- cultural vali-
dation to aid international dissemination.
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